Difluprednate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Difluprednate
Difluprednate.svg
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a609025
License data
Routes of
administration
topical dermatologic
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.041.636
Chemical and physical data
Formula C27H34F2O7
Molar mass 508.551
 NYesY (what is this?)  (verify)

Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.

Approval[edit]

On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Alcon under the tradename Durezol.

Clinical trials[edit]

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2]

References[edit]